Vaxxa ABNGM: VAXXA

VAXXA: Q3 2024 net sales more than doubled year-over-year, with EBITDA turning positive

· Issued by Vaxxa AB

Net sales more than doubled year-over-year in Q3 2024, with improved EBITDA and a strong cash position. A new platform launch and strategic hiring are set to drive further growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Vaxxa AB on 6ix

Earlier from Vaxxa

Later from Vaxxa

All Vaxxa news releases